Harris J, Jessop J D, Chaput de Saintonge D M
Br Med J. 1971 Nov 20;4(5785):463-4. doi: 10.1136/bmj.4.5785.463.
Azathioprine has been shown to reduce the steroid requirements of patients with severe rheumatoid arthritis. Twenty-seven patients treated with azathioprine have now been followed up for 30 months. At the end of this period only 10 were still taking the drug. Maximum steroid reduction occurred within the first 12 months of treatment. Some steroid-sparing effect seemed to persist after the drug was stopped. There was no evidence that azathioprine prevented radiological deterioration. No deaths occurred and toxic effects always reversed on stopping the drug.
硫唑嘌呤已被证明可降低重症类风湿关节炎患者的类固醇需求量。目前,27例接受硫唑嘌呤治疗的患者已被随访30个月。在这个阶段结束时,只有10人仍在服用该药。类固醇用量在治疗的前12个月内降至最低。停药后,一些类固醇节省效应似乎仍持续存在。没有证据表明硫唑嘌呤能阻止放射学恶化。没有发生死亡病例,停药后毒性作用总能逆转。